Jetstream Venture Fund Invests in Rejuvenation Technologies to Expand Longevity and Regenerative Medicine Portfolio
Jetstream Venture Fund has made a strategic investment in biotechnology company Rejuvenation Technologies, which is developing targeted mRNA therapies aimed at extending telomeres and treating age-related diseases. This move strengthens Jetstream's focus on longevity science and regenerative medicine. The fund already includes other innovative companies like Rejuvenate Bio and Wonderlab Bio. Rejuvenation Technologies was founded based on research from Stanford University by CEO Dr. John Ramunas, using modified mRNA delivered via proprietary lipid nanoparticles to specific organs. This approach temporarily extends telomeres without permanent activation of telomerase. The company has received over $8 million in non-dilutive grants and backing from Khosla Ventures and Y Combinator. Jetstream aims to provide retail investors with access to high-growth biotech ventures typically reserved for institutional players, reducing investment barriers through its interval fund structure.
Topics: biotechnology longevity_science mRNA_therapies telomere_extension